Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

INTRODUCTION: Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeber, Andreas, Zimmer, Kai, Kocher, Florian, Puccini, Alberto, Xiu, Joanne, Nabhan, Chadi, Elliott, Andrew, Goldberg, Richard M, Grothey, Axel, Shields, Anthony F, Battaglin, Francesca, El-Deiry, Wafik S, Philip, Philip A, Marshall, John L, Hall, Michael, Korn, W Michael, Lenz, Heinz-Josef, Wolf, Dominik, Feistritzer, Clemens, Spizzo, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684832/
https://www.ncbi.nlm.nih.gov/pubmed/33229504
http://dx.doi.org/10.1136/esmoopen-2020-000942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684832/
https://www.ncbi.nlm.nih.gov/pubmed/33229504
http://dx.doi.org/10.1136/esmoopen-2020-000942

Ejemplares similares